BioSpace News Archive

US Biologic, Inc. announces USDA Conditional Licensure of its novel oral vaccine against the wildlife spread of Borrelia burgdorferi, the bacterium responsible for Lyme disease, the number one vector-borne disease in the U.S.

Psilera will be announcing their lead compound in a live virtual Clinical Compound Reveal event on May 25, 2023 from 11:30 am to 12:30 pm ET.

Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the departure of executive vice president and chief financial officer (CFO) Jay Saccaro.

Seismic Therapeutic, Inc today announced seven poster presentations and two oral presentations supporting the company’s emerging pipeline of immunoglobin (Ig) sculpting enzymes and dual-cell bidirectional (DcB) antibody programs at IMMUNOLOGY 2023, the annual meeting of the American Association of Immunologists (AAI) taking place on May 11-15 in Washington, D.C.

Affini-T Therapeutics, Inc. today announced that preclinical data for its oncogenic driver program targeting KRAS G12D, AFNT–212, will be presented at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting in Los Angeles, California.

DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced the appointment of Bret Christensen, previously chief commercial officer of Insulet, as president, chief executive officer and a member of the board of directors (the board).

NorthStar Medical Radioisotopes , LLC, today announced that it will be participating in the upcoming 2023 Guggenheim Radiopharmaceuticals Day.

Fractyl Health to Present Preclinical Proof-of-Concept Data for Rejuva ® Pancreatic Gene Therapy Platform Program at the American Society of Gene & Cell Therapy Congress.

Boehringer Ingelheim announced today that it has launched clinical development of its first-in-class IL-11 inhibitor antibody BI 765423 with a Phase 1 study ( NCT05658107 ) to assess the safety, tolerability, and pharmacokinetics in healthy volunteers.

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will be participating in the Lytham Partners Spring 2023 Investor Conference taking place virtually on Thursday, May 18, 2023.